Restricted Research - Award List, Note/Discussion Page

Fiscal Year: 2018

1982  The University of Texas at San Antonio  (75800)

Principal Investigator: Hung, Chiung-Yu (Principal Investigator)  

Total Amount of Contract, Award, or Gift (Annual before 2011): $ 1,899,426

Exceeds $250,000 (Is it flagged?): Yes

Start and End Dates: 7/1/18 - 6/30/23

Restricted Research: YES

Academic Discipline: COS BIOLOGY  

Department, Center, School, or Institute: South Texas Center for Emerging Infectious Diseases (STCEID)  

Title of Contract, Award, or Gift: 1R01 AI 135005-01A1: Development of a multivalent vaccine against Coccidioides infection

Name of Granting or Contracting Agency/Entity: NIH Natl Inst of Allergy/Infectious Dise
CFDA Link: HHS
93.855

Program Title: N/A
CFDA Linked: Allergy, Immunology and Transplantation Research

Note:

Our central hypothesis is that an optimized multivalent rCPA2 antigen loaded in glucan-chitin particles (GCPs) as an adjuvant/delivery system with an FDA-approved carrier can be used to elicit a broad spectrum of protective immunity against both species of Coccidioides. The novel design of the GCP-based adjuvant/co-delivery platform allows for customization so that it can be adapted for use in vaccines against other medically important pathogens, where a robust and durable Th17 and/or Th1 immunity is essential for protection. Upon completion of this project, we expect that a novel multivalent antigen loaded in GCP adjuvant delivery platform will be generated for advancement into clinical trials for assessment of its safety and protective efficacy against Our central hypothesis is that an optimized multivalent rCPA2 antigen loaded in glucan-chitin particles (GCPs) as an adjuvant/delivery system with an FDA-approved carrier can be used to elicit a broad spectrum of protective immunity against both species of Coccidioides. The novel design of the GCP-based adjuvant/co-delivery platform allows for customization so that it can be adapted for use in vaccines against other medically important pathogens, where a robust and durable Th17 and/or Th1 immunity is essential for protection. Upon completion of this project, we expect that a novel multivalent antigen loaded in GCP adjuvant delivery platform will be generated for advancement into clinical trials for assessment of its safety and protective efficacy against coccidioidomycosis.

Discussion: No discussion notes

 

Close Window